METHOD OF OPHTHALMIC SURGERY AND KIT THEREFOR

• US 20090198213A1
• Filed: 01/29/2009
• Published: 08/06/2009
• Est. Priority Date: 01/30/2008
• Status: Active Grant

• Current Assignee: Santen Pharmaceutical Company Limited, Seikagaku Corporation, Takaya Tanaka
• Original Assignee: Santen Pharmaceutical Company Limited, Seikagaku Corporation, Takao Tanaka
• Inventors: TANAKA, Takao
• Granted Patent: US 9,539,138 B2
• Time in Patent Office: Days
• US Class Current: 604/506
• CPC Class Codes: A61F 9/0008 Introducing ophthalmic products into the ocular cavity or retaining products therein putting in contact lenses A61F9/0061; introducing or retaining media in cavities of the body in general A61M31/00
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/007 Methods or devices for eye surgery
• CPC Class Codes: A61K 31/728 Hyaluronic acid
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears

Abstract

A method of micro-incision ophthalmic surgery, comprising, in the order mentioned, the steps of:

(1) injecting a first viscoelastic substance through an incision site which is lateral to corneal into an anterior chamber which is in an opposite part of the incision site with discharging aqueous humor;

(2) injecting a second viscoelastic substance having higher surface tension than that of the first viscoelastic substance through the incision site into the remaining anterior chamber unfilled with the first viscoelastic substance; and

(3) injecting a third viscoelastic substance having lower surface tension than that of the second viscoelastic substance through the incision site into an area of the anterior chamber which is filled with the first viscoelastic substance until the incision site is sealed with the already injected the second viscoelastic substance.

Claims

1. A method of micro-incision ophthalmic surgery, comprising, in the order mentioned, the steps of:

(1) injecting a first viscoelastic substance through an incision site which is lateral to corneal into an anterior chamber which is in an opposite part of the incision site with discharging aqueous humor;

(2) injecting a second viscoelastic substance having higher surface tension than that of the first viscoelastic substance through the incision site into the remaining anterior chamber unfilled with the first viscoelastic substance; and

(3) injecting a third viscoelastic substance having lower surface tension than that of the second viscoelastic substance through the incision site into an area of the anterior chamber which is filled with the first viscoelastic substance until the incision site is sealed with the already injected the second viscoelastic substance.

2. The method according to claim 1, wherein the viscoelastic substance is an aqueous solution containing a sugar chain.

3. The method according to claim 2, wherein the sugar chain is a glycosaminoglycan.

4. The method according to claim 3, wherein the glycosaminoglycan is hyaluronic acid or a salt thereof.

5. The method according to claim 4, wherein a weight-average molecular weight of the hyaluronic acid or a salt thereof is in the range of from 600,000 to 4,000,000.

6. The method according to claim 1, wherein the first viscoelastic substance described in above (1) and the third viscoelastic substance described in above (3) are the same viscoelastic substance.

7. The method according to claim 1 or 6, wherein the first viscoelastic substance is an aqueous solution containing hyaluronic acid or a salt thereof, in which the hyaluronic acid of the salt thereof has a weight-average molecular weight in the range of from 600,000 to 1,200,000.

8. The method according to claim 1 or 6, wherein the second viscoelastic substance is an aqueous solution containing hyaluronic acid or a salt thereof, in which the hyaluronic acid or the salt thereof has a weight-average molecular weight in the range of from 1,500,000 to 4,000,000.

9. The method according to claim 8, wherein the hyaluronic acid or the salt thereof has a weight-average molecular weight in the range of from 1,900,000 to 3,900,000.

10. The method according to claim 4, wherein the concentration of the aqueous solution containing the hyaluronic acids or the salt thereof is about 1% (w/v).

20. An ophthalmic surgery support kit for micro-incision ophthalmic surgery according to claim 1 or 11, which comprises at least the following (A) and (B) as components;

(A) The first viscoelastic substance, and

(B) The second viscoelastic substance having higher surface tension than that of the first viscoelastic substance.

21. The kit according to claim 20, wherein the viscoelastic substance is an aqueous solution containing a sugar chain.

22. The kit according to claim 21, wherein the sugar chain is a glycosaminoglycan.

23. The kit according to claim 22, wherein the glycosaminoglycan is hyaluronic acid or a salt thereof

24. The kit according to claim 23, wherein a weight-average molecular weight of the hyaluronic acid or the salt thereof is in the range of from 600,000 to 4,000,000.

25. The kit according to claim 20, wherein the first viscoelastic substance is an aqueous solution containing hyaluronic acid or a salt thereof, in which the hyaluronic acid or the salt thereof has a weight-average molecular weight in the range of from 600,000 to 1,200,000.

26. The kit according to claim 20, wherein the second viscoelastic substance is an aqueous solution containing hyaluronic acid or a salt thereof, in which the hyaluronic acid or the salt thereof has a weight average molecular weight in the range of from 1,500,000 to 4,000,000.

27. The kit according to claim 26, wherein the hyaluronic acid or the salt thereof has a weight-average molecular weight in the range of 1,900,000 to 3,900,000.

28. The kit according to claim 23, wherein a concentration of the aqueous solution containing the hyaluronic acid or the salt thereof is about 1% (w/v).

29. The kit according to claim 25, wherein the second viscoelastic substance is an aqueous solution containing hyaluronic acid or a salt thereof, in which the hyaluronic acid or the salt thereof has a weight average molecular weight in the range of from 1,500,000 to 4,000,000.

30. The kit according to claim 29, wherein the hyaluronic acid or the salt thereof has a weight-average molecular weight in the range of 1,900,000 to 3,900,000.

11. A method of micro-incision ophthalmic surgery, comprising, in the order mentioned, the steps of:

(1) discharging an aqueous humor by anterior chamber paracentesis;

(2) injecting a second viscoelastic substance into an area around a puncture wound of anterior chamber through the puncture wound; and

(3) injecting a first viscoelastic substance having lower surface tension than that of the second viscoelastic substance into the an area of the anterior chamber which is distant from an area which has already been filled with the second viscoelastic substance through the puncture wound until the puncture wound is sealed with the already injected second viscoelastic substance.

12. The method according to claim 11, wherein the viscoelastic substance is an aqueous solution containing a sugar chain.

13. The method according to claim 12, wherein the sugar chain is a glycosaminoglycan.

14. The method according to claim 13, wherein the glycosaminoglycan is hyaluronic acid or a salt thereof.

15. The method according to claim 14, wherein a weight-average molecular weight of the hyaluronic acid or the salt thereof is in the range of from 600,000 to 4,000,000.

16. The method according to claim 11, wherein the first viscoelastic substance is an aqueous solution containing hyaluronic acid or a salt thereof, in which the hyaluronic acid or the salt thereof has a weight-average molecular weight in the range of from 600,000 to 1,200,000.

17. The method according to claim 11 or 16, wherein the second viscoelastic substance is an aqueous solution containing hyaluronic acid or a salt thereof, in which the hyaluronic acid or the salt thereof has a weight-average molecular weight in the range of from 1,500,000 to 4,000,000.

18. The method according to claim 17, wherein the hyaluronic acid or the salt thereof has a weight-average molecular weight in the range of from 1,900,000 to 3,900,000.

19. The method according to claim 14, wherein concentration of the aqueous solution containing the hyaluronic acid or the salt thereof is about 1% (w/v).